Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BCMA-targeted CAR-T Cell Injection in Relapsed/Refractory Light Chain Amyloidosis
NCT07626476Phase 1Withdrawn
- Sponsor
- Beijing Boren Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA autologous CAR T-cell injection in light-chain amyloidosis, sponsored by Beijing Boren Hospital. Primary endpoint: Adverse Events up to 2 years. Planned start Dec 2024; status: withdrawn.
02
Drugs
BCMA autologous CAR T-cell injection
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT07626476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07626476.